Your AI-Trained Oncology Knowledge Connection!
The FDA has granted accelerated approval to selpercatinib for adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion that have progressed on or after previous systemic treatment or who have no satisfactory alternative treatment options.
The FDA has granted a regular approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic non–small cell lung cancer harboring a RET gene fusion, as detected by an FDA-approved test.
Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.
The combination of fianlimab and cemiplimab demonstrated clinically meaningful activity in patients with advanced melanoma who were naïve to anti–PD-1/PD-L1 therapy.
Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.
Srdan Verstovsek, MD, PhD, discusses the benefits of rusfertide, an agent currently under evaluation in patients with polycythemia vera. In addition, he lays out the distinctions between low-risk and high-risk polycythemia vera and explains the benefits of this drug in both populations.
The Breast Cancer program at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has earned reaccreditation from the National Accreditation Program for Breast Centers.
The definitive treatment of prostate cancer has historically relied on whole-gland treatment.
The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.
Immunotherapy-based combinations elicited higher complete response rates compared with VEGF-targeted therapy when used as first-line treatment in patients with metastatic renal cell carcinoma.
The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab plus pemetrexed and platinum as a frontline treatment in unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer not harboring EGFR mutations or ALK fusions.
Treatment with immunotherapy prior to the development of brain metastases improved the median overall survival in patients with metastatic renal cell carcinoma.
Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.
An analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.
Florida Cancer Specialists & Research Institute, LLC celebrated the addition of genomic testing capabilities at its Next Generation Sequencing laboratory in Fort Myers last week with a ribbon cutting ceremony.
Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.
Health-related quality of life was maintained following treatment with nivolumab in the second- or third-line settings in patients with previously treated metastatic renal cell carcinoma, according to findings from a real-world retrospective analysis.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib for use in adult patients with marginal zone lymphoma who have received at least 1 prior anti–CD20-based therapy.
The FDA has granted a priority review to a supplemental new drug application seeking the approval of tucatinib for use in combination with trastuzumab in adult patients with HER2-positive colorectal cancer who have received at least 1 prior treatment regimen for unresectable or metastatic disease.
The FDA has granted an orphan drug designation to the novel PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of patients with pancreatic cancer.
The FDA has granted an orphan drug designation to the novel autophagy/palmitoyl protein thioesterase-1 inhibitor ezurpimtrostat for the treatment of patients with cholangiocarcinoma.
The European Medicines Agency Committee for Medicinal Products for Human Use has granted a positive opinion for axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on August 18, 2022 to celebrate the opening of its newest clinical site in Pasco County.
Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.
To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.
The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab for use in the frontline treatment of select patients with advanced or metastatic melanoma and a PD-L1 expression of less than 1% on tumor cells.
The FDA has granted an orphan drug designation to the CDK7 inhibitor SY-5609 for use as a potential therapeutic option in patients with relapsed metastatic pancreatic cancer.
Oncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.
Patients with hepatocellular carcinoma who developed treatment-related adverse effects associated with atezolizumab plus bevacizumab had improved overall survival and progression-free survival outcomes.
The European Medicines Agency Committee for Orphan Medical Products has granted an orphan drug designation to CAN-2409 for the treatment of patients with glioma.
